跳至主要内容
临床试验/JPRN-UMIN000004556
JPRN-UMIN000004556招募中未知

Pilot Study of chemotherapy with Capecitabine,Oxaliplatin and Bevacizumab for pulmonary metastases from colorectal cancer - Pilot Study of chemotherapy with Capecitabine,Oxaliplatin and Bevacizumab for pulmonary metastases from colorectal cancer

Osaka International Cancer Institute0 个研究点目标入组 20 人开始时间: 2010年11月15日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 80years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1.Body cavity fluid,and it needs drainage 2.Brain metastases or brain cancer 3.With active double cancers 4.With unresectable metastases except for pulmonary metastases 5.With cerebrovascular disease,or history of cerebrovascular disease less than 1year prior to entry 6.Surgery,biopsy with skin incision,or traumatic injury with suture less than 4weeks prior to entry 7.With thrombosis,or history of thrombosis less than 1 year prior to entry 8.Trend of bleeding or coagulation disorder 9.With uncontrolable ulcer 10.With gastrointestinal perforation,or history of gastrointestinal perforation less than 1 year prior to entry 11.With bone fracture 12.With renal disfunction,or proteiun uria 2+ less than 2 weeks prior to entry 13.With uncontrolable hypertension 14.With cardiovascular disease,or myocardinal dysfunction less than 1year prior to entry 15.History of hypersensitivity for test drugs 16.History of adverse event caused by fluoropyrimidine drugs 17.With uncontrorable diarrhea 18.With interstitial pneumonia or pulmonary fibrosis 19.With uncontrorable infection 20.With carcinomatous pleuritis 21.Nursing or pregnant females,or females who are planning to pregnancy 22.Male who are plannning to pregnancy 23.Participation in other clinical trial less than 4weeks prior to entry 24.History of bevacizumab or oxaliplatin use 25.Any other serious medical consition that would preclude study treatment

研究者

相似试验

招募中
2 期
Phase II study of chemotherapy with Capecitabine/Bevacizumab in elderly patients with advanced and recurrent colorectal cancer
JPRN-UMIN000010200Yamafuchi University Medical Bioregulation Department of Organ Regulatory Surgery30
进行中(未招募)
不适用
Phase II-Studie: Standardchemotherapie Capecitabin in Kombination mit Bevacizumab in der Erstlinientherapie beim metastasierten kolorektalen Karzinom - AIO KRK 0105
EUCTR2005-001919-21-DEMartin-Luther-Universität Halle-Wittenberg, Medizinische Fakultät, endvertreten durch den Dekan80
已完成
不适用
Phase II study of Capecitabine + oxaliplatin(CapeOx) for elderly patients with untreated metastatic gastric cancer <TCOG GI-1601>ntreated metastatic gastric cancer
JPRN-UMIN000022450The Tokyo Cooperative Oncology Group110
进行中(未招募)
不适用
Preoperative chemoradiation with capecitabine and cetuximab within a multidisciplinary therapeutic approach in patients with operable T3-T4 rectalcancer: a phase II studylocally advanced operable rectal carcinoma (cT3-T4NxM0)
EUCTR2005-003740-62-ATABCSG (Austrian Breast & Colorectal Cancer Study Group)31
进行中(未招募)
不适用
Phase II clinical trial of capecitabine and oxaliplatin plus bevacizumab as neoadjuvant treatment for patients with previously untreated unresectable liver-only metastases from colorectal cancer - BOXERMetastatic colorectal adenocarcinoma with metastases involving the liver onlyMedDRA version: 8.1Level: PTClassification code 10010035Term: Colorectal cancer stage IV
EUCTR2005-004505-29-GBRoyal Marsden NHS Trust46